Management of Active Bleeding in Cirrhotic Patients – Desmopressin Is Not Indicated

General Recommendations

In cirrhotic patients with active bleeding, desmopressin should not be used; the primary management must focus on local hemostatic measures and strategies that lower portal hypertension rather than routine correction of hemostatic abnormalities. EASL guideline (strong recommendation, 97 % agreement) supports this approach. [1][2]3
Routine correction of coagulation defects in cirrhosis is discouraged; hemostatic correction should be considered only on a case‑by‑case basis when local measures have failed. EASL guidance (moderate‑level evidence) backs this selective strategy. [1][2]4

The first step in a cirrhotic patient with rectal bleeding (or any gastrointestinal bleeding) is to determine whether the source is portal‑hypertension related (e.g., rectal varices, portal‑hypertensive colopathy) or non‑portal‑hypertension related (e.g., hemorrhoids, colonic lesions). [1][5]

Management should prioritize portal‑pressure‑lowering interventions (e.g., non‑selective β‑blockers, TIPS) and local control (endoscopic or radiologic). Routine hemostatic correction is not recommended. [1][3]
Hemostatic correction (including desmopressin) may be considered only if portal‑pressure‑lowering measures fail and bleeding persists, after multidisciplinary review. [3][4]

Step 1: Apply local hemostatic measures first (endoscopic therapy, interventional radiology). 3
Step 2: Address reversible contributing factors such as acute kidney injury, infection, and anemia, which can exacerbate bleeding. 3
Step 3: If bleeding continues despite steps 1 and 2, consider correction of hemostatic abnormalities on an individual basis; desmopressin remains not indicated unless future evidence emerges. 3

Treating acute kidney injury in cirrhotic patients improves overall hemostasis and reduces bleeding risk. [1][4]5
Optimizing anemia and other reversible conditions is preferred over the use of pro‑hemostatic agents such as desmopressin. 5

The 2022 EASL guidelines explicitly discourage routine use of antifibrinolytic agents—including desmopressin—in non‑portal‑hypertension bleeding scenarios. This reflects a strong consensus (97 % agreement) based on current evidence. [1][4]